Editorial introductions

doi: 10.1097/COH.0b013e328317c9da
Editorial introductions

Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline

Section Editors

Jonathan M. Schapiro

Jonathan M. Schapiro MD has devoted his career to HIV clinical care, research and education since completing his Fellowship in Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine Center For AIDS Research.

Dr Schapiro's research has focused on the causes of antiretroviral drug failure and interventions to optimize clinical care. This has included resistance and cross-resistance between protease inhibitors, development of new antiretroviral drugs with improved resistance profiles, the clinical utility of resistance testing and integrating resistance assays and therapeutic drug monitoring into clinical care. In addition he has been involved in the development of advanced interpretation systems for these assays. His publications have appeared in leading papers such as Annals of Internal Medicine and The Lancet.

Dr Schapiro is very active in educational initiatives; He has Co-Directed the Stanford University HIV Medicine Course and is involved in numerous programs for AIDS treating physicians. These have focused on both resource rich as well as resource limited settings.

He has served as a member of numerous international HIV expert panels and working groups including the United States Food and Drug Administration Antiviral Drugs Advisory Committee, the IAS-USA Drug Resistance Group and EuroGuidelines Group. He is a member of the Organizing and Scientific Committees of major HIV conferences and workshops.

He currently cares for HIV infected patients at the National Hemophilia Center in Israel, and remains Adjunct faculty at Stanford University where his work focuses on the Stanford HIV Drug Resistance Database.

Back to Top | Article Outline

John Erickson

Dr Erickson has a passion for discovering and developing new drugs, and has broad-based scientific expertise in structural biology, virology, medicinal chemistry, and structure-based drug design.

He has been engaged in the rational design and development of drugs to treat HIV/AIDS since the mid-1980's, when he first joined Abbott Labs after a brief stint as a faculty member at the University of Wisconsin Medical School. During his career, he has built productive and efficient drug discovery groups in the pharmaceutical industry, government, and biotechnology sectors, and his research teams have contributed to the development of several ground-breaking drugs for AIDS therapy.

At Abbott, Dr Erickson was the recipient of a major AIDS grant from the NIH, which he used to establish a multidisciplinary antiviral drug discovery program for the design of HIV protease inhibitors. Erickson's team invented a class of molecules that incorporated a novel symmetric architecture, which was designed to structurally complement the symmetric active site of the enzyme. Based on this invention, Abbott's antiviral program ultimately went on to develop two FDA approved PIs: Ritonavir and Lopinavir (Kaletra). He was elected to Abbott's prestigious Volwiler Society and received Abbott's President's Award for his contributions.

In 1991, Dr Erickson was recruited by the National Cancer Institute (NCI) to establish a multidisciplinary research team in drug design. With his new research team, Dr Erickson helped to elucidate the structural and biochemical mechanisms of drug resistance to HIV protease inhibitors, and discovered and patented a breakthrough class of HIV-1 protease inhibitors, including Darunavir, active against multi-drug resistant HIV strains. The NCI licensed this technology to Tibotec/J&J.

In 2002, Dr Erickson founded Sequoia Pharmaceuticals and the Institute for Global Therapeutics, a public charity. Sequoia is developing novel antiviral and pharmacokinetic enhancing agents. The Institute is focused on developing affordable new medicines and approaches to treat global HIV/AIDS.

Dr Erickson earned a B.A. in Biology from SUNY at Buffalo, a M.S. in Molecular Biology from Vanderbilt University, and a Ph.D. in Virology from The University of Western Ontario. He has authored over 140 research papers, is an inventor on over 30 patents, and has been a frequent invited speaker at national and international meetings on HIV/AIDS and drug design.

© 2008 Lippincott Williams & Wilkins, Inc.